Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis | The Journal of Immunology
Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease) | SpringerLink
Frontiers | Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders | Immunology
Frontiers | Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows | Immunology
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent - Journal of the American Academy of Dermatology
Psoriasis | NEJM
JCM | Free Full-Text | Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity | HTML
Mechanisms of psoriasis - ScienceDirect
Mechanism of Action | ILUMYA® (tildrakizumab-asmn) HCP
Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis | IntechOpen
Medicinal Plants to Calm and Treat Psoriasis Disease | IntechOpen
Recent advances in understanding psoriasis | F1000Research
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses: Trends in Immunology
Psoriasis pathogenesis and the development of novel targeted immune therapies - Journal of Allergy and Clinical Immunology
Psoriasis | NEJM
Frontiers | Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients | Genetics
Psoriasis | NEJM
Pathogenesis of psoriasis and development of treatment - Ogawa - 2018 - The Journal of Dermatology - Wiley Online Library
Selenium nanoparticles produce a beneficial effect in psoriasis by reducing epidermal hyperproliferation and inflammation | Journal of Nanobiotechnology | Full Text
New insights of T cells in the pathogenesis of psoriasis | Cellular & Molecular Immunology
IJMS | Free Full-Text | Psoriasis Pathogenesis and Treatment | HTML
